摘要
Allogeneic hematopoietic stem cell transplantation （alloHSCT） has been used to treat a variety of hematologic malignancies and non-malignant diseases.Hematopoietic stem cell donor selection is based on identical human leukocyte antigen （HLA） related or unrelated donor matching with the recipient.Donor-recipient HLA mismatching has been associated with graft-versus-host disease （GVHD）,increased mortality and decreased disease free survival （DFS）.1 Not all patients are able to find a suitable donor,as no more than 25% of patients have an HLA-identical sibling.Much effort has been devoted to the establishment of bone marrow （BM） registries for HSCT.Keywords：human leukocyte antigen; transplantation; donor; genotyping
Allogeneic hematopoietic stem cell transplantation （alloHSCT） has been used to treat a variety of hematologic malignancies and non-malignant diseases.Hematopoietic stem cell donor selection is based on identical human leukocyte antigen （HLA） related or unrelated donor matching with the recipient.Donor-recipient HLA mismatching has been associated with graft-versus-host disease （GVHD）,increased mortality and decreased disease free survival （DFS）.1 Not all patients are able to find a suitable donor,as no more than 25% of patients have an HLA-identical sibling.Much effort has been devoted to the establishment of bone marrow （BM） registries for HSCT.Keywords：human leukocyte antigen; transplantation; donor; genotyping
基金
This work was supported by the National Natural Science Foundation of China （No.81072435
81273266）,the Outstanding Medical Academic Leader Program of Jiangsu Province （No.LJ 201138）,the Science and Technology Key Project on Clinical Medicine of Jiangsu Province （No.BL2013013）,and the Key Laboratory Foundation of Suzhou （No.SZS201001
SZS0702）.
